Jasper Therapeutics is expected to report a Q3 2026 consensus loss of $0.06 per share on revenue of $6.00 million, while the current stock price of $16.86 remains well below the average analyst target of $251.67 following a recent reverse split.
Investors are primarily focused on the clinical timeline for briquilimab, particularly the planned commencement of the Phase 2b study for chronic spontaneous urticaria (CSU) in the second half of 2026.
Supporting this outlook is the company's recent acquisition of Kira Pharmaceuticals, which added the complement inhibitor KP104 to the pipeline. Backed by a $132 million financing round, management is expected to provide updates on its cash runway, which is currently projected to extend through 2028.